VEGFA and cancer: With the 2004 FDA approval of bevacizumab (Avastin), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), to treat metastatic colorectal cancer in combination with 5-fluorouracil (5-FU), antiangiogenesis therapy has emerged as an essential new strategy for cancer treatment [2].